Human glioblastoma in mouse

Publications

The following includes selected recent publications from our lab.

Highlights in IO: next-generation CAR-T therapy for glioblastoma. [Review]

Yamaguchi J, Okada H.

J Immunother Cancer. 2026 Apr 12; 14 (4): e014670. doi: 10.1136/jitc-2025-014670. PMID: 41922085; PMCID: PMC13052789.
PubMed Link >

Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells. [Preprint]

Nejo T, Watchmaker PB, Simic MS, Yamamichi A, Lakshmanachetty S, Zhao A, Lu J, Gallus M, Benway HL, Zhu R, Almeida R, Lim WA, Okada H. 

bioRxiv. 2026 Mar 29; doi: doi: 10.64898/2026.03.26.713760. PMID: 41929125; PMCID: PMC13041868.
PubMed Link >

Focused ultrasound-enhanced cell therapy for brain tumors: Summary of roundtable discussions. [Review]

Padilla F, Arvanitis C, Bollard CM, Gallus M, De Groot J, Klein RS, Ransohoff RM, Sonabend AM, Okada H. 

Neurooncol Adv. 2026 Feb 14; 8 (1): vdag026. doi: 10.1093/noajnl/vdag026. PMID: 41773179; PMCID: PMC12950283.
PubMed Link >

The T-cell receptor repertoire: A window into pediatric brain tumor immunity. [Editorial]

Nejo T, Prins RM, Okada H. 

Neuro Oncol. 2025 Oct 14; 27 (9): 2207–2208. doi: 10.1093/neuonc/noaf112. PMID: 40305478; PMCID: PMC12526131.
PubMed Link >

Glioma-neuronal circuit remodeling induces regional immunosuppression.

Nejo T, Krishna S, Yamamichi A, Lakshmanachetty S, Jimenez C, Lee KY, Baker DL, Young JS, Chen T, Phyu SSS, Phung L, Gallus M, Maldonado GC, Okada K, Ogino H, Watchmaker PB, Diebold D, Choudhury A, Daniel AGS, Cadwell CR, Raleigh DR, Hervey-Jumper SL, Okada H.

Nat Commun. 2025 May 22; 16 (1): 4770. doi: 10.1038/s41467-025-60074-z. PMID: 40404658; PMCID: PMC12098748.
PubMed Link >

Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model.

Hatae R, Watchmaker PB, Yamamichi A, Kyewalabye K, Okada K, Phyu S, Goretsky Y, Haegelin J, Pineo-Cavanaugh P, Gallus M, Phung L, Chen T, Long H, Chuntova P, Raulet DH, Terabe M, Okada H.

Neurooncol Adv. 2025 Apr 12; 7 (1): vdaf074. doi: 10.1093/noajnl/vdaf074. PMID: 40376677; PMCID: PMC12080550.
PubMed Link >

Tumour-wide RNA splicing aberrations generate actionable public neoantigens.

Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino H, Saijo A, Du A, Grishanina NR, Woo J, Diaz A, Hervey-Jumper SL, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H. 

Nature. 2025 Mar 6; 639 (8054): 463-473. doi: 10.1038/s41586-024-08552-0. PMID: 39972144; PMCID: PMC11903331.
PubMed Link >

Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review.

Ismail FS, Gallus M, Meuth SG, Okada H, Hartung HP, Melzer N.

JAMA Neurol.. 2025 Jan 1; 82 (1): 93–103. doi: 10.1001/jamaneurol.2024.3818. PMID: 39585688.
PubMed Link >

Programming tissue-sensing T cells that deliver therapies to the brain.

Simic MS, Watchmaker PB, Gupta S, Wang Y, Sagan SA, Duecker J, Shepherd C, Diebold D, Pineo-Cavanaugh P, Haegelin J, Zhu R, Ng B, Yu W, Tonai Y, Cardarelli L, Reddy NR, Sidhu SS, Troyanskaya O, Hauser SL, Wilson MR, Zamvil SS, Okada H, Lim WA.

Science. 2024 Dec 6; 386 (6726): eadl4237. doi: 10.1126/science.adl4237. PMID: 39636984; PMCID: PMC11900893.
PubMed Link >

Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations [Review]

Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H.

Neuro Oncol. 2024 Oct 24; doi: 10.1093/neuonc/noae203. PMID: 39450490.
PubMed Link >

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Kim K, Gallus M, Xiao T, Parchure AS, Shah BR, Okada H, Diederich C, Ozhinsky E, Narsinh K.

J Vis Exp. 2024 Sep 13; 211: doi: 10.3791/66793. PMID: 39345114.
PubMed Link >

Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier

Guo Y, Lee H, Kim C, Park C, Yamamichi A, Chuntova P, Gallus M, Bernabeu MO, Okada H, Jo H, Arvanitis C

Nat Commun. 2024 Sep 13; 15 (1): 8021. doi: 10.1038/s41467-024-52329-y. PMID: 39271721; PMCID: PMC11399249.
PubMed Link >

Activating the dark genome to illuminate cancer vaccine targets

Kwok DW, Okada H, Costello JF

Nat Genet. 2024 Aug 1; 56 (9): 1770-1771. doi: 10.1038/s41588-024-01850-3. PMID: 39223317; PMCID: PMC11456370.
PubMed Link >

Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas? [Review]

Phung LH, Nejo T, Okada H

Vaccines (Basel). 2024 Aug 1; 12 (8): 862. doi: 10.3390/vaccines12080862. PMID: 39203988; PMCID: PMC11359082.
PubMed Link >

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H

Neuro Oncol. 2024 Aug 8; doi: 10.1093/neuonc/noae149. PMID: 39115195.
PubMed Link >